News stories about Array BioPharma (NASDAQ:ARRY) have trended somewhat positive this week, Accern Sentiment reports. The research firm identifies positive and negative media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Array BioPharma earned a daily sentiment score of 0.16 on Accern’s scale. Accern also gave media headlines about the biopharmaceutical company an impact score of 45.5003125029299 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
These are some of the media headlines that may have impacted Accern Sentiment Analysis’s scoring:
Shares of Array BioPharma (NASDAQ:ARRY) opened at $13.98 on Thursday. The company has a current ratio of 5.43, a quick ratio of 5.43 and a debt-to-equity ratio of 0.54. Array BioPharma has a 12-month low of $6.73 and a 12-month high of $14.13. The firm has a market cap of $2,750.00, a PE ratio of -18.89 and a beta of 1.91.
Array BioPharma (NASDAQ:ARRY) last issued its earnings results on Tuesday, October 31st. The biopharmaceutical company reported ($0.22) earnings per share for the quarter, meeting the consensus estimate of ($0.22). Array BioPharma had a negative net margin of 89.30% and a negative return on equity of 158.70%. The business had revenue of $29.75 million for the quarter, compared to analyst estimates of $33.74 million. During the same period in the previous year, the business earned ($0.20) EPS. The firm’s revenue was down 24.2% on a year-over-year basis. analysts anticipate that Array BioPharma will post -0.99 earnings per share for the current year.
Several research firms have recently issued reports on ARRY. Cantor Fitzgerald set a $15.00 price objective on shares of Array BioPharma and gave the stock a “buy” rating in a report on Wednesday, January 3rd. Zacks Investment Research downgraded shares of Array BioPharma from a “hold” rating to a “sell” rating in a report on Thursday, January 4th. BidaskClub upgraded shares of Array BioPharma from a “sell” rating to a “hold” rating in a report on Friday, December 22nd. Piper Jaffray Companies restated an “overweight” rating and set a $18.00 price objective (up previously from $14.00) on shares of Array BioPharma in a report on Wednesday, September 20th. Finally, Jefferies Group lifted their target price on shares of Array BioPharma to $13.00 and gave the company a “buy” rating in a research report on Friday, December 22nd. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and eight have issued a buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $14.10.
In other Array BioPharma news, COO Andrew R. Robbins sold 282,874 shares of the business’s stock in a transaction dated Monday, December 18th. The shares were sold at an average price of $10.72, for a total value of $3,032,409.28. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Ron Squarer sold 819,671 shares of the business’s stock in a transaction dated Tuesday, December 19th. The shares were sold at an average price of $10.86, for a total transaction of $8,901,627.06. The disclosure for this sale can be found here. 3.18% of the stock is currently owned by insiders.
TRADEMARK VIOLATION NOTICE: “Somewhat Positive Media Coverage Somewhat Unlikely to Affect Array BioPharma (ARRY) Share Price” was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this news story on another domain, it was copied illegally and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this news story can be accessed at https://www.dispatchtribunal.com/2018/01/11/somewhat-positive-media-coverage-somewhat-unlikely-to-affect-array-biopharma-arry-share-price.html.
Array BioPharma Company Profile
Array BioPharma Inc is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. The Company’s programs include approximately three cancer drugs, binimetinib, encorafenib and selumetinib (partnered with AstraZeneca, PLC).
Receive News & Ratings for Array BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Array BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.